ArticleAntimicrobial agents and chemotherapy2013
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 63 citations in OpenAlex.
- Trial
- Carbadox, a veterinary growth promoter exhibits anticlostridial activity through induction of oxidative stress in Clostridioides difficile.Gut pathogens · 2026Article
- Ionomycin Exhibits Potent and Selective Bactericidal Activity Against Clostridioides difficile Through Calcium-Dependent Membrane Disruption.MicrobiologyOpen · 2026Article
- Review
- Review
- Review of the Impact of Biofilm Formation on RecurrentMicroorganisms · 2023Review
- Review
- Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- Isolation, molecular typing and antimicrobial resistance ofFrontiers in veterinary science · 2022Article
- The small acid-soluble proteins of Clostridioides difficile are important for UV resistance and serve as a check point for sporulation.PLoS pathogens · 2021Article
- Teicoplanin Suppresses VegetativeAntibiotics (Basel, Switzerland) · 2021Article
- Characterization of an Endolysin TargetingInternational journal of molecular sciences · 2021Article
- Article
- An Analysis ofOpen forum infectious diseases · 2020Article
- Treatment issues in recurrentFEMS microbes · 2020Review
- Fidaxomicin for the treatment ofFuture microbiology · 2020Article
- Review
- Novel FR-900493 Analogues That Inhibit the Outgrowth ofACS omega · 2018Article
- Hierarchical recognition of amino acid co-germinants during Clostridioides difficile spore germination.Anaerobe · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactorial. Here, we tested effects of FDX, its metabolite OP-1118, and vancomycin on spore germination and determined that none affected the initiation of spore germination but all inhibited outgrowth of vegetative cells from germinated spores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.